1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow NKTR-255: new trials by email Literature Review of NKTR-255 trials Research Report on NKTR-255
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) NKTR-255, Durvalumab - Lung Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 39 | 2023-01-10 | 2026-07-29 |
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Avelumab, Sacituzumab Govitecan (SG), M6223 - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 256 | 2022-08-17 | 2026-09-28 |
| Study of NKTR 255 in Combination With Cetuximab in Solid Tumors NKTR-255, Cetuximab - Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Nektar Therapeutics | 25 | 2020-10-30 | 2025-06-08 |
Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Neoplasms (1)
EMD Serono Research & Development Institute, Inc. (1) · M.D. Anderson Cancer Center (1) · Nektar Therapeutics (1)
United States (3) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Steven Lin, MD (1)
2023 (1)